1. Home
  2. AKBA vs GHM Comparison

AKBA vs GHM Comparison

Compare AKBA & GHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKBA
  • GHM
  • Stock Information
  • Founded
  • AKBA 2007
  • GHM 1936
  • Country
  • AKBA United States
  • GHM United States
  • Employees
  • AKBA N/A
  • GHM N/A
  • Industry
  • AKBA Biotechnology: Pharmaceutical Preparations
  • GHM Industrial Machinery/Components
  • Sector
  • AKBA Health Care
  • GHM Industrials
  • Exchange
  • AKBA Nasdaq
  • GHM Nasdaq
  • Market Cap
  • AKBA 336.2M
  • GHM 319.4M
  • IPO Year
  • AKBA 2014
  • GHM N/A
  • Fundamental
  • Price
  • AKBA $1.91
  • GHM $38.88
  • Analyst Decision
  • AKBA Strong Buy
  • GHM Buy
  • Analyst Count
  • AKBA 2
  • GHM 1
  • Target Price
  • AKBA $5.75
  • GHM $35.00
  • AVG Volume (30 Days)
  • AKBA 2.3M
  • GHM 35.0K
  • Earning Date
  • AKBA 11-07-2024
  • GHM 11-08-2024
  • Dividend Yield
  • AKBA N/A
  • GHM N/A
  • EPS Growth
  • AKBA N/A
  • GHM 102.05
  • EPS
  • AKBA N/A
  • GHM 0.44
  • Revenue
  • AKBA $169,879,000.00
  • GHM $187,915,000.00
  • Revenue This Year
  • AKBA N/A
  • GHM $12.28
  • Revenue Next Year
  • AKBA $3.23
  • GHM $9.99
  • P/E Ratio
  • AKBA N/A
  • GHM $75.30
  • Revenue Growth
  • AKBA N/A
  • GHM 11.45
  • 52 Week Low
  • AKBA $0.80
  • GHM $15.82
  • 52 Week High
  • AKBA $2.48
  • GHM $34.73
  • Technical
  • Relative Strength Index (RSI)
  • AKBA 68.47
  • GHM 80.40
  • Support Level
  • AKBA $1.30
  • GHM $27.41
  • Resistance Level
  • AKBA $2.01
  • GHM $29.55
  • Average True Range (ATR)
  • AKBA 0.12
  • GHM 1.21
  • MACD
  • AKBA 0.04
  • GHM 0.76
  • Stochastic Oscillator
  • AKBA 78.52
  • GHM 100.00

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About GHM Graham Corporation

Graham Corporation designs and manufactures mission-critical fluid, power, heat transfer, and vacuum technologies for the defense, space, energy, and process industries. The company also services and sells spare parts for its equipment. It designs and manufactures custom-engineered vacuum, heat transfer, cryogenic pump and turbomachinery technologies.

Share on Social Networks: